GlassScriptPhysician profile
Bernard G Harrell
NPI 1871575852
$3,893.29
in general payments reported to CMS, 2019-2025
22 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $461 · 2021: $462 · 2022: $602 · 2023: $679 · 2024: $589 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $974.77 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $578.08 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $469.57 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $364.02 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $222.43 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $214.18 | 2019-2022 | |
| Abbvie INC. | $198.16 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.66 | 2019-2024 | Xifaxan |
| Amgen INC. | $112.91 | 2019-2023 | Repatha |
| Glaxosmithkline, LLC. | $104.51 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.68 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $92.85 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.89 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $58.64 | 2022-2025 | |
| Allergan, INC. | $43.14 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.78 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $30.19 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.94 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.57 | 2021 | |
| Inspire Medical Systems, INC. | $14.22 | 2025 | Inspire |
| Horizon Therapeutics Plc | $13.75 | 2021 | |
| Sumitomo Pharma America, INC. | $13.35 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.